This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally.View HPTX key stats
Hyperion Therapeutics Inc - HPTX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Hyperion Therapeutics Inc as a
Buy with a ratings score of B.
Report Snippet: We rate HYPERION THERAPEUTICS INC (HPTX) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.